PAPER Qiu Z, Farnsworth SL, Mishra A, Hornsby PJ
SEARCH RESULTS
330026 RESULTS
PAPER Garcia-Martin E, Rodriguez-Mena D, Satue M, Almarcegui C, Dolz I, Alarcia R, Seral M, Polo V, Larrosa JM, Pablo LE
Electrophysiology and optical coherence tomography to evaluate Parkinson disease severity.
Invest Ophthalmol Vis Sci. 2014 Feb 4;55(2):696-705. PubMed: 24425856PAPER Dorval V, Mandemakers W, Jolivette F, Coudert L, Mazroui R, De Strooper B, Hébert SS
Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models.
PLoS One. 2014;9(1):e85510. Epub 2014 Jan 10 PubMed: 24427314Ann Van der Jeugd
KU LeuvenLeuven, Belgium
Gregor Macdonald
Janssen PharmaceuticalsBeerse, Belgium, Belgium
Alzheimer's Association International Conference 2014
CONFERENCE 2014-07-12 00:00:00-2014-07-17 00:00:00 Bella Center A/S, Copenhagen, Denmark 12 July 2014 to 17 July 2014 View Conference Website 0
J Liu
University of Illinois College of Medicine
PAPER Pivtoraiko VN, Abrahamson EE, Debnath ML, Paljug WR, Klunk WE, Mathis CA, Mufson EJ, Dekosky ST, Ikonomovic MD
Increased posterior cingulate pyroglutamate Abeta 42 levels correlate with impaired cognition and increased [H-3]PiB binding in mild cognitive impairment and mild/moderate Alzheimer’s disease
Program No. 545.17/F19. 2012 Neuroscience Meeting Planner. New Orleans, LA: Society for Neuroscience, 2012. Online.FUS
ALZPEDIA Originally identified as a pro-oncogene, FUS came to the attention of neurodegenerative disease research in 2009, when mutations in this gene were linked to amyotrophic lateral sclerosis (ALS). FUS mutations account for about 4 percent of inherited ALS, i
Marco Lorenzi
INRIA Sophia AntipolisSophia Antipolis, France
PAPER Maksimovich IV
Vascular factors in Alzheimer’s disease
Health. 2012 Sep; 4(9A):735-42.PAPER Maksimovich IV
Certain New Aspects of Etiology and Pathogenesis of Alzheimer's Disease
Adv Alzheimer Dis. 2012 Dec;1(3):68-76.PAPER Bell RD, Ehlers MD
Breaching the blood-brain barrier for drug delivery.
Neuron. 2014 Jan 8;81(1):1-3. PubMed: 24411725Kim Clinton
GE
PAPER Wischik CM, Bentham P, Wischik DJ, Seng KM
Tau aggregation inhibitor (TAI) therapy with RemberTM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks
Alzheimers Dement. 2008;4(S2):T167.Current Filters
No filters selected